西妥昔单抗联合ＦＯＬＦＩＲＩ方案治疗晚期大肠癌的临床观察

目的：观察和评价西妥昔单抗（爱必妥）联合ＦＯＬＦＩＲＩ方案治疗国人晚期大肠癌患者的疗效及毒副反应。方法：回顾性分析２００６年６月～２００８年１２月我院经病理证实的晚期大肠癌患者４３例，爱必妥４００ｍｇ／ｍ２，第１次；以后２５０ｍｇ／ｍ^２，每周１次，或者５００ｍｇ／ｍ^２，每２周１次；伊立替康（开普拓）１８０ｍｇ／ｍ^２，第１天，静滴３０分钟；亚叶酸钙２００ｍｇ／ｍ^２，第１、２天，静滴２小时；氟尿嘧啶（５－ＦＵ）４００ｍｇ／ｍ^２，静推，第１、２天，５－ＦＵ６００ｍｇ／ｍ^２，持续静滴２２小时，第１、２天，每２周重复。每例至少接受４周期化疗后评价疗效。结果：全组４３例均可评价，有效率（ＣＲ＋ＰＲ）为３４．９％ （１５／４３），ＳＤ４８．８％ （２１／４３），ＰＤ１６．３％ （７／４３）。中位疾病进展时间（ＴＴＰ）８．９个月，中位生存期（ＯＳ）１９．３个月。治疗相关毒副反应主要为皮疹、迟发性腹泻及中性粒细胞减少。结论：西妥昔单抗联合ＦＯＬＦＩＲＩ方案治疗国人晚期大肠癌疗效肯定，可使大部分患者临床获益，其毒副反应可以耐受。

Cetuximab plus FOLFIRI for patients with advanced colorectal cancer

Objective：To evaluate the efficacy and adverse effects of cetuximab with FOLFIRI regimen for the Chinese advanced colorectal cancer.Methods：From June,2006 to December,2008,retrospective analysis 43 cases advanced colorectal cancer were proved by pathology.Cetuximab was given by 400mg/m2 on day 1 with subsequent weekly doses of 250mg/m2 or 500mg/m2 every 2 weeks.Irinotican was given by 180mg/m2,d1,dripping into vein in 30 minutes;LV 200mg/m2,d1,d2;5-FU 400mg/m2,blous,d1,d2,5-FU 600mg/m2,civ22h,d1,d2,every 2 weeks was a cycle.All the patients recieved at least 4 cycles of chemotherapy.Results：In 43 patients,34.9%（15/43） of response rate was observed and SD was 48.8%（21/43）,PD was 16.3%（7/43）.MST was 19.3months,TTP was 8.9months.The common treatment related adverse events were skin rash,delayed diarrhea and neutropenia.Conclusion：Cetuximab combined with FOLFIRI for the Chinese patients with advanced colorectal cancer is an active regimen.It gives the most patients clinical benifit and its side effects are tolerable.